Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorFOGUIM, F. T.
dc.contributor.authorROBERT, M. G.
dc.contributor.authorGUEYE, M. W.
dc.contributor.authorGENDROT, M.
dc.contributor.authorDIAWARA, S.
dc.contributor.authorMOSNIER, J.
dc.contributor.authorAMALVICT, R.
dc.contributor.authorBENOIT, N.
dc.contributor.authorBERCION, R.
dc.contributor.authorFALL, B.
dc.contributor.authorMADAMET, M.
dc.contributor.authorPRADINES, B.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorTHE FRENCH NATIONAL REFERENCE CENTRE FOR IMPORTED MALARIA STUDY GROUP
dc.date.accessioned2020-06-11T09:18:08Z
dc.date.available2020-06-11T09:18:08Z
dc.date.issued2019-08-28
dc.identifier.issn1475-2875en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/7878
dc.description.abstractEnBACKGROUND: Resistance to all available anti-malarial drugs has emerged and spread including artemisinin derivatives and their partner drugs. Several genes involved in artemisinin and partner drugs resistance, such as pfcrt, pfmdr1, pfK13 or pfpm2, have been identified. However, these genes do not properly explain anti-malarial drug resistance, and more particularly clinical failures observed in Africa. Mutations in genes encoding for Plasmodium falciparum proteins, such as P. falciparum Acetyl-CoA transporter (PfACT), P. falciparum UDP-galactose transporter (PfUGT) and P. falciparum cyclic amine resistance locus (PfCARL) have recently been associated to resistance to imidazolopiperazines and other unrelated drugs. METHODS: Mutations on pfugt, pfact and pfcarl were characterized on 86 isolates collected in Dakar, Senegal and 173 samples collected from patients hospitalized in France after a travel in African countries from 2015 and 2016 to assess their potential association with ex vivo susceptibility to chloroquine, quinine, lumefantrine, monodesethylamodiaquine, mefloquine, dihydroartemisinin, artesunate, doxycycline, pyronaridine and piperaquine. RESULTS: No mutations were found on the genes pfugt and pfact. None of the pfcarl described mutations were identified in these samples from Africa. The K784N mutation was found in one sample and the K734M mutation was identified on 7.9% of all samples for pfcarl. The only significant differences in ex vivo susceptibility according to the K734M mutation were observed for pyronaridine for African isolates from imported malaria and for doxycycline for Senegalese parasites. CONCLUSION: No evidence was found of involvement of these genes in reduced susceptibility to standard anti-malarial drugs in African P. falciparum isolates.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enColl_IDLIC
dc.title.enLow polymorphisms in pfact, pfugt and pfcarl genes in African Plasmodium falciparum isolates and absence of association with susceptibility to common anti-malarial drugs
dc.title.alternativeMalar Jen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1186/s12936-019-2919-3en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed31455301en_US
bordeaux.journalMalar Jen_US
bordeaux.page293en_US
bordeaux.volume18en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue1en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Malar%20J&rft.date=2019-08-28&rft.volume=18&rft.issue=1&rft.spage=293&rft.epage=293&rft.eissn=1475-2875&rft.issn=1475-2875&rft.au=FOGUIM,%20F.%20T.&ROBERT,%20M.%20G.&GUEYE,%20M.%20W.&GENDROT,%20M.&DIAWARA,%20S.&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée